- Home
- SNGX vs ICU Comparison
SNGX vs ICU Comparison
Compare SNGX & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- ICU
- Stock Information
- Founded
- SNGX 1987
- ICU 2018
- Country
- SNGX United States
- ICU United States
- Employees
- SNGX N/A
- ICU N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- ICU Health Care
- Exchange
- SNGX Nasdaq
- ICU Nasdaq
- Market Cap
- SNGX 9.6M
- ICU 10.3M
- IPO Year
- SNGX 1987
- ICU N/A
- Fundamental
- Price
- SNGX $3.16
- ICU $2.00
- Analyst Decision
- SNGX
- ICU
- Analyst Count
- SNGX 0
- ICU 0
- Target Price
- SNGX N/A
- ICU N/A
- AVG Volume (30 Days)
- SNGX 46.1K
- ICU 24.8K
- Earning Date
- SNGX 11-08-2024
- ICU 11-13-2024
- Dividend Yield
- SNGX N/A
- ICU N/A
- EPS Growth
- SNGX N/A
- ICU N/A
- EPS
- SNGX N/A
- ICU N/A
- Revenue
- SNGX $364,183.00
- ICU $68,000.00
- Revenue This Year
- SNGX N/A
- ICU N/A
- Revenue Next Year
- SNGX $76.64
- ICU $344.44
- P/E Ratio
- SNGX N/A
- ICU N/A
- Revenue Growth
- SNGX N/A
- ICU N/A
- 52 Week Low
- SNGX $1.83
- ICU $1.70
- 52 Week High
- SNGX $19.20
- ICU $42.93
- Technical
- Relative Strength Index (RSI)
- SNGX 41.70
- ICU 39.05
- Support Level
- SNGX $2.93
- ICU $1.70
- Resistance Level
- SNGX $3.35
- ICU $2.04
- Average True Range (ATR)
- SNGX 0.19
- ICU 0.19
- MACD
- SNGX -0.01
- ICU 0.01
- Stochastic Oscillator
- SNGX 37.10
- ICU 33.33
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.